We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a win for Allergan, the U.S. Court of Appeals for the Federal Circuit upheld a federal court ruling blocking Sandoz’s proposed generic of Allergan’s eye drops Combigan (brimodine/timolol). Read More
The Patent Trial and Appeal Board (PTAB) said it’s opening an inter partes review (IPR) of patents covering Alexion Pharmaceuticals’ immunosuppressive drug Soliris (eculizumab), following a petition by Amgen. Read More
PhRMA said it “strongly encourages” the FDA’s new “integrated review process,” which combines assessments by the agency’s different disciplines into a single document for new drug applications and efficacy supplements. Read More
The court ruled that the state “met its burden” in proving that J&J’s misleading marketing and promotion of opioids caused the state’s incurred costs. Read More
The U.S. Patent Trial and Appeal Board (PTAB) has decided to conduct an inter partes review of Opiant Pharmaceutical’s patent covering its opioid-overdose treatment Narcan (naloxone). Read More
A federal court in Delaware invalidated two of Amgen’s patents for the cholesterol drug Repatha (evolocumab), siding with Sanofi and Regeneron. Read More